novo nordisk products - Search News

News

Novo Nordisk to develop new obesity pills

The Wall Street Journal on MSN · 2d

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

UPI on MSN · 1d

Novo Nordisk, U.S. biotech company team up to create obesity pills

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and cardiometabolic diseases.

Novo Nordisk ousts CEO

Reuters on MSN · 1d

From insulin to Ozempic, history of Novo Nordisk's CEOs

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli Lilly .

pharmaphorum · 1d

Novo Nordisk's dropping share price spells the end for CEO

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation and former Novo Nordisk CEO, Lars Rebien Sørensen, is joining the pharma company's board, initially as an observer.

Financial Times · 1d

Novo Nordisk ousts boss as Ozempic maker battles slump

Novo Nordisk has announced that chief executive Lars Fruergaard Jørgensen will step down just days after the pioneering maker of obesity drugs cut its profit forecast. The Danish group said on Friday that it had started the search for a new chief executive after agreeing with Jørgensen that new leadership was needed.

Zacks Investment Research on MSN1d

Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

Novo Nordisk strikes deal with Septerna to develop obesity pills

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

GlobalData on MSN3d

Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Strategic Leadership Transition

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

1d

Novo Nordisk, Charter & Cox, Take Two: Trending Tickers

CEO Lars Fruergaard Jørgensen is set to step down. Charter (CHTR) and Cox Communications announce a merger in a $34.5 billion ...

2d

Ignore The Noise - Novo Nordisk Is A Clear Buy

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results